TIZIANA LIFE SCIENCES LTD

NASDAQ: TLSA (Tiziana Life Sciences Ltd)

Last update: 11 hours ago

1.47

-0.01 (-0.68%)

Previous Close 1.48
Open 1.46
Volume 99,777
Avg. Volume (3M) 336,478
Market Cap 171,766,560
Price / Book 43.64
52 Weeks Range
0.630 (-57%) — 1.91 (29%)
Earnings Date 23 Jun 2025 - 8 Jul 2025
Diluted EPS (TTM) -0.110
Total Debt/Equity (MRQ) 2.69%
Current Ratio (MRQ) 1.02
Operating Cash Flow (TTM) -1.53 M
Levered Free Cash Flow (TTM) -8.99 M
Return on Assets (TTM) -84.13%
Return on Equity (TTM) -250.49%

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Mixed Bearish
Biotechnology (Global) Mixed Bearish
Stock Tiziana Life Sciences Ltd Mixed Mixed

AIStockmoo Score

0.0
Analyst Consensus NA
Insider Activity NA
Price Volatility -4.5
Technical Moving Averages 5.0
Technical Oscillators -0.5
Average 0.00

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
TLSA 172 M - - 43.64
CVAC 1 B - 5.81 1.62
REPL 956 M - - 2.09
SANA 952 M - - 4.55
VIR 781 M - - 0.750
ZVRA 699 M - - 17.05

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.

Sector Healthcare
Industry Biotechnology
Investment Style Small Value
% Held by Insiders 43.06%
% Held by Institutions 2.73%

Ownership

Name Date Shares Held
Dauntless Investment Group, Llc 31 Mar 2025 1,739,574
Zhang Financial Llc 31 Mar 2025 96,260
Kovitz Investment Group Partners, Llc 31 Mar 2025 79,365
Ewa, Llc 31 Mar 2025 47,601
Bison Wealth, Llc 31 Dec 2024 42,795
Bison Wealth, Llc 31 Mar 2025 42,795

No data within this time range.

No data within this time range.

Date Type Details
13 Jun 2025 Announcement Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
13 Jun 2025 Announcement Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
13 Jun 2025 Announcement Tiziana Life Sciences to Present at the Bio International Convention
13 Jun 2025 Announcement Tiziana Life Sciences to Present at the Bio International Convention
23 May 2025 Announcement Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
23 May 2025 Announcement Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
15 May 2025 Announcement Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
15 May 2025 Announcement Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease
12 May 2025 Announcement Tiziana Life Sciences Announces Purchase of Shares by Chairman
12 May 2025 Announcement Tiziana Life Sciences Announces Purchase of Shares by Chairman
09 May 2025 Announcement Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
09 May 2025 Announcement Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab
06 May 2025 Announcement Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
06 May 2025 Announcement Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
23 Apr 2025 Announcement Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
23 Apr 2025 Announcement Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2025 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria